COMPLETED

The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The overall goal of this project is to compare the absolute quantification of myocardial perfusion done by using CT myocardial perfusion imaging (CT-MPI) and the coronary flow measured by using CT Fractional Flow Reserve analysis (CT-FFR) to the gold standard represented by PET myocardial perfusion imaging (PET-MPI).

Official Title

MyocardiAl CT Perfusion and Coronary Flow: a CompreHensive Cardiac CT Myocardial Perfusion Imaging (MPI)/Fractional Flow Reserve (FFR) and PET-CT MPI Evaluation (The MATCH Investigation)

Quick Facts

Study Start:2021-06-16
Study Completion:2024-09-24
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04316676

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 85 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Referred for a clinically indicated CT-MPI for CAD assessment
  2. * Must provide written informed consent prior to any study-related procedures being performed
  3. * Must be willing to comply with all clinical study procedures
  1. * Pregnant or nursing females. The possibility of pregnancy will be excluded by testing (serum or urine ßHCG) within 24 hours before study agent administration, or if the woman has previous surgical sterilization, or if the woman is post menopausal, with minimum one (1) year history without menses.
  2. * Currently taking or has taken within 48 hours the following excluded medications:
  3. * ActoPlus Met (Pioglitazone + metformin)
  4. * Avandamet (Rosiglitazone + metformin)
  5. * Fortamet (metformin)
  6. * Glucovance (Glyburide +metformin)
  7. * Glucophage (metformin)
  8. * Glucophage extended-release (XR) (metformin)
  9. * Glumetza (metformin)
  10. * Janumet (Sitagliptin + metformin)
  11. * Metformin
  12. * Metaglip (Glipizide + metformin)
  13. * Riomet (metformin)
  14. * Acute psychiatric disorder
  15. * Unwilling to comply with the requirements of the protocol
  16. * Previously entered this study
  17. * Known hypersensitivity to iodinated contrast material, beta-blockers, or pharmaceutical stressors used in this study
  18. * Suffers from claustrophobia
  19. * Impaired renal function (GFR \< 45 ml/min)
  20. * Acute hypotension (\<100 mm Hg systolic)
  21. * 2nd or 3rd degree atrioventricular (AV) block

Contacts and Locations

Principal Investigator

Carlo De Cecco, MD, PhD
PRINCIPAL_INVESTIGATOR
Emory University

Study Locations (Sites)

Emory University Hospital
Atlanta, Georgia, 30322
United States

Collaborators and Investigators

Sponsor: Emory University

  • Carlo De Cecco, MD, PhD, PRINCIPAL_INVESTIGATOR, Emory University

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-06-16
Study Completion Date2024-09-24

Study Record Updates

Study Start Date2021-06-16
Study Completion Date2024-09-24

Terms related to this study

Keywords Provided by Researchers

  • Atherosclerosis
  • Cardiovascular disease
  • Myocardial ischemia
  • Imaging
  • Nuclear medicine
  • Radiology

Additional Relevant MeSH Terms

  • Coronary Artery Disease